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dendritic cells using glycopolymers with picomolar
aﬃnity for DC-SIGN†
Daniel A. Mitchell,*ab Qiang Zhang,c Lenny Voorhaar,c David M. Haddleton, c
Shan Herath,d Anne S. Gleinich,a Harpal S. Randeva,ab Max Crispin,e Hendrik Lehnert,f
Russell Wallis,g Steven Pattersond and C. Remzi Becer *h
The human C-type lectin DC-SIGN (CD209) is a signiﬁcant receptor on the surface of dendritic cells (DCs)–
crucial components of host defense that bridge the innate and adaptive immune systems. A range of linear
glycopolymers, constructed via controlled radical polymerization techniques have been shown to interact
with DC-SIGN with aﬃnities in the physiologically active range. However, these ﬁrst generation
glycopolymers possess limited structural deﬁnition and their eﬀects on DCs were not known. Here we
report the development of star-shaped mannose glycopolymers with the aim of targeting the clustered
domain arrangement of DC-SIGN and these were shown to bind with picomolar aﬃnity. Increased
secretion of IL-10 with simultaneous decrease in secreted IL-12p70 occurred in activated DCs incubated
with star-shaped glycopolymers – a cytokine secretion pattern characteristic of wound-healing tissue
environments. Incorporating stellar architecture into glycopolymer design could be key to developing
selective and very high-aﬃnity therapeutic materials with distinct immunomodulatory and tissue repair
potential.Introduction
The recognition of repeating molecular patterns is a major
function of the human immune system, enabling it to interact
with and interpret various biological structures. These include
the surfaces of pathogens such as viruses, fungi and bacteria, in
addition to host structures such as glycoproteins and apoptotic
cells.1,2 C-type lectins are a major class of pattern recognition
molecules in humans that interact with complex carbohydrates
such as microbial polysaccharides and oligosaccharides present
on human and viral glycoproteins and glycolipids.3 In partic-
ular, the C-type lectin DC-SIGN (dendritic cell-specicniversity of Warwick, Coventry CV2 2DX,
ck.ac.uk
e NHS Trust, Coventry CV2 2DX, United
wick, Coventry CV4 7AL, United Kingdom
ollege School of Medicine, London SW10
, Oxford OX1 3QU, United Kingdom
any
f Leicester, Leicester LE1 9HN, United
, Queen Mary University, London E1 4NS,
k
tion (ESI) available. See DOI:intercellular adhesion molecule-3 grabbing nonintegrin;
CD209; CLEC4L) is signicantly implicated in human disease
through its interactions with viral carbohydrates on HIV and
mycobacterial lipoarabinomannans (e.g. tuberculosis), in addi-
tion to its ability to transduce intracellular signaling events and
inuence dendritic cell responses.4–7 DC-SIGN is also important
in the proper responses to specic apoptotic cell uptake by
dendritic cells (DCs).2DCs are especially important components
of the human immune system owing to their roles as highly
eﬃcient surveillance entities and professional antigen pre-
senting cells. DCs are the only cell type with the ability to acti-
vate na¨ıve T lymphocytes, making them very powerful bridges
between innate and adaptive immunity.8 NMR analyses of
DC-SIGN-oligosaccharide interactions in solution suggest
discrete binding modes of the carbohydrate-recognition
domain for distinct glycan types that in turn are thought to
drive diﬀerent cell signaling pathways.9 Furthermore, the
distribution of DCs (and DC-SIGN-positive cells such as selected
macrophage subpopulations) within discrete regions of tissues
of the human body makes them attractive targets for site-
specic therapeutic intervention in a broad range of diseases
with immune system involvement.10,11
Designed glycopolymers have been successfully generated
for high aﬃnity interactions with human DC-SIGN.12–15 This has
included the development of size- and sequence-controlled
polymers, in addition to conformation-controlled polymers
and glycoconjugates, collectively oﬀering a diverse range ofThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Representative chemical structures of the mannose glycopol-
ymers. R ¼ Br in the initiator structure.
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View Article Onlinestrategies for DC-SIGN targeting and exploitation. However, the
concept of polymer architecture as a rational design strategy for
DC-SIGN targeting with these classes of glycopolymer has yet to
be employed and furthermore, the impact of advanced glyco-
polymers on dendritic cell function has yet to be investigated
(Fig. 1). Knowledge of the tetrameric structure of DC-SIGN,
wherein four mannoside-selective carbohydrate recognition
domains (CRDs) are clustered at the top of a coiled-coil stalk
projecting from the cell surface,16,17 allows for the rational
construction of novel glycopolymers for further aﬃnity
enhancement and potential biological impact. Understanding
of the role of DC-SIGN stimulation in dendritic cell responses
holds potential for eﬃcient, high aﬃnity ligands to serve as
immunomodulators as well as antiviral agents. The main text of
the article should appear here with headings as appropriate.Materials and methods
Instrumentation
NMR spectra were recorded on a Bruker DPX-300 and DPX-400
using deuterated solvents. FTIR spectra were recorded on
a Bruker Vector 22 FTIR spectrometer. For SEC a Varian PL
390-LC system was used, equipped with refractive index and
viscosimetry detectors, using either CHCl3 or DMF (LiBr 1 g l
1)
as the eluent (1 ml min1). Data analysis was performed using
Cirrus soware andmolecular weights were determined relative
to Polymer Labs pMMA standards. The LCST of the glycopol-
ymers was determined by measuring the cloud point of
a 5 mg ml1 solution of the polymer in water with a Stanford
Research Systems OptiMelt MPA100.Synthesis of 2-methacrylic acid 3-trimethylsilanyl-prop-2-ynyl
ester (TMSMA)
A ask was charged with 3-trimethylsilanyl-prop-2-yn-1-ol
(25.0 g, 195 mmol) and triethylamine (41.0 ml, 294 mmol) in
THF (250 ml) and cooled with dry ice. A solution of 2-methyl-
acryloyl chloride (23.0 ml, 235 mmol) in THF (50 ml) was added
drop wise. The mixture was stirred for 1 hour while cooling with
dry ice and stirred overnight at room temperature, during which
yellow coloured salts were formed. The mixture was puried on
a basic Al2O3 column and the solvent was removed under
reduced pressure, leaving behind a clear yellow liquid. The yield
was 35.0 g (178 mmol, 92%) 1H NMR (CDCl3, 298 K, 300 MHz)This journal is © The Royal Society of Chemistry 2017d (ppm) ¼ 0.18 (s, 9H, Si(CH3)3); 1.96 (m, 3H, CH3C]CH2); 4.76
(s, 2H, OCH2); 5.62 (m, 1H, C]CHH); 6.17 (m, 1H, C]CHH).
Typical atom transfer radical polymerization procedure
A Schlenk tube was charged with initiator (1.0 mmol), monomer
(50 mmol), N-(ethyl)-2-pyridylmethanimine ligand (2.0 mmol)
and toluene (same volume as monomer). Two diﬀerent
methods have been used to remove the oxygen from the solu-
tion, which have been found to be equally eﬀective. The rst
method was a freeze–pump–thaw cycle, which was executed
three times. The secondmethod was bubbling the solution with
nitrogen for at least 20 minutes. A second Schlenk tube was
charged with Cu(I)Br (1.0 mmol) and a stirring bar and the
oxygen was removed by evacuating and subsequently lling the
tube with nitrogen three times. The solution was transferred to
the second tube using a cannula and a vacuum to start the
transfer. The solution was heated to 90 C while being kept
under nitrogen atmosphere for the entire duration of the reac-
tion. Samples were taken periodically using a degassed syringe
in case of the kinetic experiments. The polymerization was
stopped by cooling the mixture to room temperature and
exposing it to oxygen. The mixture was diluted with CH2Cl2
(approximately same volume as mixture) and passed through
a basic Al2O3 column. The polymer was precipitated into a 5 : 1
vol/vol methanol/water mixture (pTMSMA). The solid was iso-
lated by ltration and dried in a vacuum oven overnight. In
most experiments with the star-shaped initiators the amount of
toluene used was higher to prevent star–star coupling. This was
either twice (for 5-arm star) or three times (8-arm star) the
volume of the monomer.
Deprotection of pTMSMA
The pTMSMA (0.5 g) was dissolved in THF (35 ml) and glacial
acetic acid (0.22 ml, 1.5 equiv. with respect to the TMS groups)
was added. The solution was bubbled with nitrogen and cooled
with dry ice for at least 15 minutes. A 0.2 M solution of TBAF in
THF (50 ml, 4.0 equiv.) was added dropwise with a syringe while
stirring the solution and cooling with dry ice. The dry ice was
removed aer 30 minutes and the mixture was stirred overnight
at room temperature. The mixture was concentrated under
reduced pressure, puried on a silica column and concentrated
again. The polymer was precipitated in petroleum ether cooled
with dry ice and acetone. The white powder was isolated by
ltration and dried in a vacuum oven overnight. The depro-
tection was conrmed by the appearance of a peak at 2.5 ppm in
the 1H NMR and the disappearance of the 0.2 ppm peak.
Synthesis of a-mannose azide
Sodium azide (7.26 g, 111 mmol), D-(+)-mannose (2.00 g,
11.1 mmol) and triethylamine (15.5 ml, 111 mmol) were dis-
solved in water (40 ml) and cooled to 0 C. 2-Chloro-1,3-
dimethylimidazolinium chloride (5.61 g, 33.3 mmol) was
added and themixture was stirred for 1 hour at 0 C. The solvent
was removed under reduced pressure and EtOH (40 ml) was
added. The solids were removed by ltration and the solution
was puried on a long Amberlite IR-120 column, using EtOH asChem. Sci., 2017, 8, 6974–6980 | 6975
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View Article Onlinethe eluent. The mixture was checked with FTIR to conrm the
removal of all sodium azide (n ¼ 2030 cm1). The solvent was
removed under reduced pressure, water (30 ml) was added and
the mixture was washed with dichloromethane (5  15 ml). The
solvent was removed under reduced pressure, water (10 ml) was
added and the solution was freeze-dried overnight to give
a-mannose azide (1.59 g, 78 mmol, 70%) as an oﬀ-white solid.
1H NMR (D2O, 298 K, 400 MHz) d (ppm) ¼ 5.45 (1H), 3.95–3.60
(6H). 13C NMR (D2O, 298 K, 400 MHz) d (ppm) ¼ 89.72 (C1),
74.65, 69.86, 69.77, 66.40, 60.83 (C6). FT-IR (H2O) n (cm
1) ¼
2112 (N3).
Mannose azide clicking to propargyl polymers
A solution containing propargyl polymer (100 mg, 0.81 mmol
propargyl groups), mannose azide (213 mg, 1.05 mmol) and
CuBr (116 mg, 0.81 mmol) in DMSO (10 ml) was bubbled with
nitrogen for 20 minutes. Ethyl ligand (216 mg, 1.61 mmol) was
added and the solution was bubbled with nitrogen for several
more minutes. The solution was subsequently stirred at
ambient temperature for two days. The mixture was puried by
dialysis (MWCO: 1000) against distilled water for two days,
while changing the water at least four times. It was then
concentrated under reduced pressure and freeze-dried
overnight.
Glycopolymer synthesis and characterization
Before the click reactions could take place, the propargyl groups
of the pTMSMA polymers need to be deprotected by removal of
the TMS group. This was performed by reacting the polymer
with CH3COOH and TBAF in THF. The deprotection can be
followed by 1H NMR (Fig. S1†). The peak of the TMS group at
0.2 ppm disappears and a peak appears at 2.5 ppm for the
propargylic proton. Aer removing the water from the reaction
mixture, EtOH was added to lter the unreacted sodium azide
from the mixture. However, some of the sodium azide was still
soluble in EtOH, as is shown in the FTIR spectrum in Fig. S2.†
As sodium azide can form explosive compounds when it is
brought into contact with halogenated solvents, it was neces-
sary to remove this from the mixture before continuing with
subsequent purication steps. It was found that this last trace of
sodium azide could be removed on an Amberlite IR-120 column
using EtOH as the eluent. TEA was also removed from the
mixture with this column. The remaining DMC was removed by
washing the mixture in water with CH2Cl2. Mannose azide was
attached to each of the diﬀerent synthesized propargyl polymers
using click chemistry. The reaction can be observed using 1H
NMR through the appearance of a triazole peak at 8.30 ppm
(Fig. S3†). The peaks at 6.0 ppm and 5.4–4.3 ppm are from the
mannose. The kinetic plot for the polymerization of TMSMA
shows that it takes roughly 15 minutes for the polymerization to
initiate (Fig. S5†). Aer that the conversion is linear up to at
least 95%. The increase of Mn with conversion is almost linear
within the margin of error. PDI values are all very close together
around 1.3. The homopolymerization of TMSMA using the
8-arm initiator was performed in 75% solvent to avoid coupling
of the star polymers. The rst-order kinetic plot is linear up to6976 | Chem. Sci., 2017, 8, 6974–698050% conversion. A short initiation period was observed that was
also seen in the homopolymerization of TMSMA with the
disulde initiator. The increase in molecular weight is mostly
linear with relation to the conversion (PDI  1.25). The theo-
retical molecular weight of the synthesized linear, 5 arm and
8 arm glycopolymers have been calculated as 35 700 g mol1,
37 100 g mol1, and 39 600 g mol1, respectively. The measured
number average molecular weight of the linear, 5-arm, and
8-arm glycopolymers were found as 41 000 g mol1,
42 100 g mol1, and 45 600 g mol1, respectively.
Protein expression and surface plasmon resonance
Soluble recombinant DC-SIGN was generated in E. coli and
puried via aﬃnity chromatography usingmannose–sepharose,
as described previously and immobilized16 on GLM sensor chips
via amine coupling for use in the Bio-Rad ProteOn XPR36
instrument (Bio-Rad Laboratories, Hercules, USA).12 Glycopol-
ymer samples were dissolved in running buﬀer (10 mM HEPES
pH 7.4, 150mMNaCl, 5 mMCaCl2, 0.01% (v/v) Tween-20, 0.01%
(w/v) NaN3) and owed over sensor chips at a ow rate of
25 ml ml1 at 25 C. Sensorgram data were collected and refer-
ence subtraction performed against a blank channel treated
with amine coupling activators and subsequently blocked with
1 M ethanolamine. Kinetic parameters were determined using
the Bia-evaluation soware (GE Healthcare) utilizing heteroge-
neous ligand tting models.
Blood samples
Peripheral bloodmononuclear cells (PBMCs) were isolated from
blood leukocyte cones (National Blood Transfusion Service, UK)
by density gradient centrifugation with Lymphoprep™ 1077
(PAA Laboratories, GmbH, UK) followed by a 50% Percoll
(Sigma, UK) gradient to obtain a high-density fraction enriched
in lymphocytes and a low-density fraction enriched in mono-
cytes. Fractions were aliquoted and stored in liquid N2 until
required.
Generation of dendritic cells
Monocyte derived dendritic cells (moDCs) were isolated from
the monocyte rich fraction by magnetic bead separation using
anti-CD14 coated magnetic beads (Miltenyi Biotec). Puried
monocytes were cultured in complete medium (RPMI contain-
ing 10% FBS, 100 IU ml1 penicillin, 0.1 mg ml1 streptomycin,
and 2 mM L-glutamine; Sigma-Aldrich) supplemented with
GM-CSF (100 ng ml1) and IL-4 (50 ng mLl1; R&D Systems),
this being replenished every other day. On day 7, DCs were
harvested, washed twice and resuspended in serum-free RPMI-
1640 prior to staining for ow cytometry.
Flow cytometry
Dendritic cells were harvested, washed and stained with either
5-arm polymer-FITC, 8-arm polymer-FITC, a linear polymer-
FITC or gp120-FITC (generated from soluble recombinant
gp120 produced in HEK cells as previously described) at the
concentrations indicated in the results. To assess the ability ofThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinethe polymers to bind to the gp120 site, DCs were incubated with
unlabeled polymer (at the concentrations indicated in the
results) for 45 minutes at room temperature and then treated
with gp120-FITC (1 mg ml1) for a further 30 minutes at room
temperature. To determine binding of gp120 to CD4+ cells, DCs
and lymphocytes were rstly incubated with unlabeled gp120 at
1 mgml1 for 45min at room temperature and then stained with
anti-CD4-APC, anti-CD3-Percp, and gp120-FITC for a further
30 minutes. Following all the incubations, cells were washed
and xed with BD stabilizing xative (BD Biosciences).
Unstained DCs were used as a control. One hundred thousand
cells were acquired within a live gate using a 3-laser congu-
ration LSRII ow cytometer (BD Biosciences, USA), and analysed
by FlowJo (Tree Star Inc, USA).Cytokine assays
Sets of dendritic cell cultures, derived from four separate
donors, were incubated with 1 mg ml1 gp120 and also dened
quantities of the three species of glycopolymer (8-arm, 5-arm
and linear; at 1, 3 and 10 mg ml1). Aer 24 hours, one group of
DC cultures was activated with 1 mg ml1 lipopolysaccharide
(LPS; Sigma, Poole, UK) and 20 ng ml1 interferon gamma
(IFN-g), the other le unstimulated. Supernatants (100 ml) from
the assorted cultures were recovered aer a further 24 hours via
centrifugation at 2000 rpm. Samples were diluted 1 : 1 in
DMEM cell culture mediumwithout supplements and duplicate
measurements were made using Luminex bead immunoassay.
A panel of nine cytokines was analyzed simultaneously using
the commercial Bio-Rad Th1 and Th2 kit within the Bio-plex 200
Multiplex System in accordance with manufacturer instructions
(Bio-Rad Laboratories, Hercules, USA). Quantitative readouts
were obtained for the following cytokines: tumor necrosis factor
alpha (TNF-a), IFN-g, interleukins (IL)-2, IL-4, IL-5, IL-10,
IL-12p70, IL-13, and granulocyte/monocyte-colony stimulating
factor (GM-CSF).
Research using human material was carried out in accor-
dance with institutional guidelines issued by the University of
Warwick and Imperial College London, and with the principles
expressed in the Declaration of Helsinki. Ethical approval was
obtained from the Riverside Research Ethics Committee and
informed written consent was obtained prior to patient blood
collection. Data from human-derived material were processed
anonymously.Results and discussion
Carbohydrates in the form of oligosaccharides and poly-
saccharides represent a large, crucial and exciting family of
molecules in the development of novel therapeutics. Uncover-
ing the roles of complex carbohydrates in human physiology
and disease coincides with the advancement of our under-
standing of carbohydrate-binding receptors such as DC-SIGN.
Initially identied as a molecule exploited by HIV-1 in order
to promote viral traﬃcking and within-host survival, it has since
emerged recently that DC-SIGN is central to important physio-
logical processes such as healthy responses during apoptoticThis journal is © The Royal Society of Chemistry 2017cell clearance and foeto-maternal tolerance.2,18 Studies into the
impact of glycan ligands for DC-SIGN on immune cells indicate
that this receptor is capable of driving anti-inammatory and
immunosuppressive cell signaling with major eﬀects on gene
expression and cellular responses.6,7 Whilst undesirable in the
context of certain infections, these responses are benecial in
the active processes of wound healing and the resolution of
inammatory episodes. It is becoming increasingly clear that
these tissue repair and protection mechanisms are highly active
and require advanced immune system involvement. Of signi-
cance is the association of molecules such as DC-SIGN with
tissue environments such as placenta, uterus and gut, where
tight control of tissue growth & stability and blood supply in the
presence of abundant non-self material is essential.11
Understanding the structure and function of DC-SIGN allows
us to design and prepare advanced synthetic ligands for this
molecule and investigate opportunities for exploiting its anti-
inammatory properties. The strategy of generating dened
star-shaped glycopolymers (GPs) to achieve enhanced binding
to the tetrameric conguration of DC-SIGN has been very
successful, showing increases in aﬃnity exceeding an order of
magnitude, in addition to demonstrating strong interactions
with DCs. We speculate that the star-shaped architecture spans
the four CRDs within the DC-SIGN tetramer, increasing the
strength of the interaction and potentially inuencing the
consequences of DC-SIGN engagement. It is assumed that
DC-SIGN can only transduce signals when clustered in multi-
meric complexes with multiple glycan ligands expressed on
a large surface area, although small ligands such as Lewis-x
oligosaccharides have been shown to drive signaling and gene
expression responses in DCs via DC-SIGN engagement.
Furthermore, NMR analyses of DC-SIGN–oligosaccharide
interactions in solution suggest discrete binding modes of the
carbohydrate-recognition domain for distinct glycan types that
in turn are thought to drive diﬀerent cell signaling pathways.
Therefore, the consequences of DC-SIGN engagement by gly-
copolymers could be inuenced and even tuned by variations in
sugar composition, architecture and size.
Star-shaped GPs bind to recombinant DC-SIGN with sub-
nanomolar aﬃnity. Interaction analysis in real time via
surface plasmon resonance (SPR) demonstrated distinct and
strong binding between immobilized DC-SIGN and all of the
GPs examined (Fig. 2), consistent with previous studies.12 As
expected, the star-shaped GPs showed greater aﬃnity compared
with the linear GP of equal molecular weight and dissociation
rates (koﬀ) were markedly slow, in keeping with strong multi-
valent interactions with the oligomeric DC-SIGN protein.
Apparent KD values of 65.1 pM and 72.5 pMwere determined for
the star-shaped 5-arm and 8-arm glycopolymers, respectively
(Table 1).Star-shaped glycopolymers show improved and dose-
dependent binding to human dendritic cells
To determine whether the polymers bound directly to dendritic
cells (DCs), DCs were stained with FITC-labeled polymers at
a range of polymer concentrations. Fig. 3A–C shows that all GPsChem. Sci., 2017, 8, 6974–6980 | 6977
Fig. 2 Real-time analysis of GP interactions with DC-SIGN. SPR sen-
sorgrams were collected at 25 C and a ﬂow rate of 25 mL min1 and
demonstrate clear interactions between linear glycopolymer P1 (Panel
A), 5-arm star glycopolymer P2 (Panel B) and 8-arm star glycopolymer
P3 (Panel C) and immobilized DC-SIGN extracellular domain. The
sensorgram curves illustrate slow dissociation, especially of the 5-arm
and 8-arm GPs during the wash phase (indicated by the guideline at
900 s).
Fig. 3 Concentration-dependent glycopolymer binding to DCs.
Dendritic cells were labeled with the indicated concentration of FITC-
labeled glycopolymers/glycoprotein (Panel A – Linear P1; Panel B – 5-
arm star P2; Panel C – 8-arm star P3; and Panel D – gp120) and
analyzed by ﬂow cytometry. The data are representative of one of 3
donors.
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View Article Onlinebound to DCs to some degree with the 5-arm and 8-arm glyco-
polymers binding better than the linear polymer. We also
assessed the binding of gp120 to DCs and found that binding
followed a similar prole to the star-shaped glycopolymers
(Fig. 3D). In a direct comparison between the polymers and
gp120, we found that the 5-arm and 8-arm GPs bound with
a similar intensity as compared to the gp120 at the highest dose
of 10 mg ml1 (see ESI†).
In addition to assessing the intrinsic binding of GPs to DCs
we also determined whether they exerted any measurable
inuence on the activation status of the treated DCs by
analyzing their cell-surface markers. We found that following
24 hours of exposure to the polymers generated here, there was
no signicant change in DC expression of the canonical acti-
vation markers CD80, CD83, CD86 or HLA-DR when examining
cells from three separate donors.
There is a likelihood that these mannose glycopolymers also
interact with dendritic cell and macrophage subpopulations
that express the mannose receptor (CD206), in addition to
specialised endothelial cells that express receptors such as
DC-SIGNR (CD299). Where the very high aﬃnity interactions
between the star-shaped glycopolymers and DC-SIGN couldTable 1 Binding kinetics and apparent KD values of the linear, 5-arm
star-shaped, and 8-arm star-shaped glycopolymers
Run Type kon (M
1 s1) koﬀ (s
1) KD (M)
P1 Linear 1.24  106 1.34  104 1.08  1010
P2 5-Arm star 1.01  106 7.33  105 7.25  1011
P3 8-Arm star 0.93  106 6.03  105 6.51  1011
6978 | Chem. Sci., 2017, 8, 6974–6980possess signicant selectivity would be in discrete tissue spaces
such as inamed synovium associated with rheumatoid
arthritis, where salient subpopulations of DC-SIGN-positive
macrophages are upregulated.19Competition of glycopolymers with gp120 for binding sites on
dendritic cells due to cellular CD4 expression
To determine whether the polymers competed with the gp120
for the same cellular binding site, we incubated DCs with
unlabeled polymers and then stained the cells with FITC-
labeled gp120 (Fig. 4). Our results show that although there
was a slight shi in binding when polymer was present, none of
the polymers signicantly abrogated gp120 binding.
To assess whether this was due to the gp120 using more than
one binding partner on cell surfaces, we looked at determining
the expression of the major gp120 ligand – CD4 – on both DCs
and T cells. Our results show that gp120 is able to bind to CD4
molecules on both DCs and T cells – a site to which gp120
binding is not carbohydrate-dependent (Fig. 5). Consequently
our results demonstrate that the polymers bind to separate sites
on cells from those utilized and possibly preferred by gp120.
The ow cytometry studies involving HIV gp120 interactions
with DCs raise a very important issue in the use of glycopol-
ymers as agents for viral blockade. The presence of CD4 on
moDCs (and also native peripheral DC populations) serves as
a very eﬀective adhesion route for HIV, such that polymer-based
barrier preparations could be compromised in vivo. This would
be consistent with in vivo ndings that DC-SIGN is associated
with parenteral but not mucosal traﬃcking of HIV.20However, it
is yet to be known whether the presence of glycopolymers could
aﬀect HIV infection of CD4+ T cells in trans and whether gly-
copolymers would be eﬀective in blocking DC interactions with
other dangerous glycosylated viruses that are known to interactThis journal is © The Royal Society of Chemistry 2017
Fig. 4 Competition of polymer vs. gp120 binding to dendritic cells.
Dendritic cells were ﬁrstly incubated with the indicated concentration
of unlabeled polymer (Panel A – Linear P1; Panel B – 5-arm star P2;
Panel C – 8-arm star P3; Panel D – summary of polymers at
10 mg ml1) and then probed with FITC gp120. Cells were analyzed by
ﬂow cytometry and the data represent one of 3 donors.
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View Article Onlinewith DC-SIGN such as hepatitis C virus (HCV), Ebola and
Dengue.Glycopolymers modulate cytokine production by activated
DCs
Cytokine analysis was carried out on supernatants recovered
from DCs exposed to glycopolymers and consensus activation
stimuli (LPS plus IFN-g). Prior to supernatant harvesting, the
DCs appeared healthy and normal in the presence of glycopol-
ymers, suggesting that these materials were tolerated and not
markedly toxic at the quantities used (1–10 mg ml1). Measured
cytokine secretion levels were negligible in all of the DC cultures
that were not stimulated with LPS and IFN-g, suggesting that
the GPs themselves do not invoke major secreted DC activation
responses. In DC cultures activated with LPS and IFN-g, key
cytokines such as TNF-a were up-regulated in all cultures, asFig. 5 Competition binding of gp120 against CD4. Dendritic cells and
lymphocytes were ﬁrst incubated with an unlabeled gp120 and then
stained with an anti-CD4 antibody. Cells were analyzed by ﬂow
cytometry and the data represents one of 2 donors.
This journal is © The Royal Society of Chemistry 2017expected, and the exposure of DCs to star-shaped GPs led to
signicant changes in the secretion of two cytokines – IL-10 and
IL-12p70. Levels of secreted IL-10 were signicantly increased
only in supernatants from activated DCs exposed to the 8-arm
and 5-arm GPs, and only at the highest concentration used
(10 mg ml1; Fig. 6A). Equivalent quantities of the linear GP did
not invoke signicant changes in IL-10 secretion. Levels of
IL-12p70 were signicantly reduced by all three species of GP in
a dose dependent manner (Fig. 6B–D). Interestingly, the linear
GP showed an eﬀect in reducing IL-12p70 secretion (Fig. 6B).
This suggests that whilst showing lower levels of binding to
DC-SIGN and to DCs, linear GPs may still inuence certain DC
responses.
The changes in cytokine secretion by DCs invoked by the
star-shaped polymers are consistent with those observed in
mammalian wound healing. IL-10 is a potent immunosup-
pressive cytokine with broad eﬀects on inammation and its
mediators.21 IL-12p70 is a pro-inammatory cytokine and
a potent inhibitor of angiogenesis (blood vessel growth).22 The
combination of IL-10 increase and IL-12 decrease represents
a rapid and eﬀective means of reducing inammation and
restoring organized blood ow to a site of tissue injury. In
general, qualitative changes in secretion of these two cytokines
are in keeping with the consequences of DC-SIGN engagement
by biologically-sourced mannosylated ligands. However, a key
diﬀerence is that in the case of the glycopolymers, the chemical
denition is very precise. In contrast, biological high mannose
ligands such as gp120, yeast mannan and mycobacterialFig. 6 Eﬀects of glycopolymers on cytokine secretion by activated
DCs. Cells were incubated with GPs before activation with LPS and
IFN-g and multiplex cytokine assay. IL-10 secretion was signiﬁcantly
increased in DC cultures from 4 donors incubated with 8-arm star P3
and 5-arm star P2 GPs at 10 mg ml1 compared with controls, but not
with linear GP P1 (Panel A). IL-12p70 secretion was signiﬁcantly
decreased compared to controls in cells exposed to increasing
concentrations of linear GP P1 (Panel B), 5-arm star GP P2 (Panel C)
and 8-arm star GP P3 (Panel D) (all P values calculated from paired
t-tests).
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View Article Onlinelipoarabinomannan are notoriously heterogeneous.23–25
Furthermore, the low cost of polymer precursors and the simple
synthesis workow make the glycopolymers described here an
attractive and aﬀordable means of generating abundant, water-
soluble material with advanced immunological activity.
Conclusions
To summarize, we report the synthesis and characterization of
highly water-soluble advanced glycopolymer sets of dened size
and shape designed to interact profoundly with the key human
lectin DC-SIGN. Biophysical studies demonstrate remarkable
glycopolymer-DC-SIGN interactions with aﬃnities in the pico-
molar range and positive binding to human monocyte-derived
dendritic cells. Star-shaped glycopolymers invoke signicant
changes in the production of two key cytokines, IL-10 and
IL-12p70, when incubated with dendritic cells at pharmaco-
logically realistic concentrations. Importantly, IL-10 levels rise
and IL-12 levels fall in response to the glycopolymers and this
cytokine release pattern is reminiscent of tissue environments
associated with active wound healing, anti-inammation, and
also healthy pregnancy at the feto-maternal interface. In our
experiments, however, the glycopolymers do not aﬀect the
ability of HIV gp120 to interact with monocyte-derived dendritic
cells – previously a major direction for both DC-SIGN and gly-
copolymer research. We propose novel roles for glycopolymers
of this kind, shiing the focus away from HIV prophylaxis
towards the treatment of conditions that require immune
modulation that promotes wound healing and inammatory
resolution. Examples of such conditions could include burns &
chronic skin lesions, in addition to chronic inammatory
diseases with immunological involvement such as rheumatoid
arthritis, multiple sclerosis and Crohn's disease.
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